Abstract
Introduction
Mammalian cell growth is dependent upon Ca 
Ca
2q occur in response to growth factors and CaM w x peaks in mass during G1 1-3 . The ablation or w x inhibition of CaM arrests cells during G1 4-6 and cellular transformation can lead to elevated levels of w x CaM 7 . CaM has a number of potential targets through which it could act to channel Ca 2q signals into the growth regulatory machinery, including the w x family of CaM-dependent protein kinases 8 . Of the 6 different CaM kinases, which include CaMK I through IV, myosin light chain kinase and phosphory-lase kinase, only CaMK-I and CaMK-II are uniw x formly expressed in proliferative cells 8, 9 . CaMK-IV is regulated by other kinases and has been implicated in transcriptional regulation, but is specific to neuw x ronal and reproductive cells 10, 11 . In mammalian cells, CaMK-II is encoded by four known genes: a, b, g and d, to give rise to over a dozen CaMK-II subtypes, presumably through alternative splicing w x 12-14 .
Ž Ž .
2q
CaMK-II the type II multifunctional Ca rCaM . kinase was originally discovered as a major protein in differentiated neuronal tissue where it was implicated in long-term potentiation and neurotransmitter w x release 15,16 . CaMK-II has since been discovered w x in yeast, mold, fruit flies and humans [17] [18] [19] . It has been linked to the regulation of carbohydrate metabolism, membrane fusion and the cell cycle in w x non-neuronal cells [20] [21] [22] [23] [24] . CaMK-II activity and polypeptides have been found in proliferative cells in w x culture 23,25 and CaMK-II has been reported to be activated within 20 sec of growth induction by serum, w x PDGF, EGF or bradykinin 26,27 . CaMK-II inhibitory drugs arrest mammalian cells in G1 and S w x phase 22,23,28 and block the expression of early response genes, such as fos, which are necessary for w x cell growth 11,29 .
CaMK-II isozymes are encoded as single polypeptides, each containing a catalytic, a regulatory, a variable and an association domain with predicted masses between 54 and 60 kDa. The catalytic domain has features common to most serinerthreonine protein kinases. The regulatory domain is the site of CaM binding and autophosphorylation, through which CaMK-II can sustain its own activity after a Ca 2q w x 2q surge 9,30 . The generation of Ca -independent or autonomous activity in this manner is believed to comprise the molecular basis for long-term functions of CaMK-II. The regulatory domain is adjacent to a region of high variability where most differences between the four CaMK-II genes and among the w x splice variants are located 9 . It is believed that this region serves in part as an elongated tether between the catalytic and association domains and is therefore exposed to other proteins enabling it to associate with w x sub-cellular organelles or substrates 12,14 . The association domain is responsible for the oligomerization of CaMK-II, a trait unique to this member of the CaM kinase family.
Neuronal-specific functions of multifunctional CaMK-II are believed to be carried out by a and b CaMK-II, while the widespread distribution of g and d suggests that they may be involved in functions w x common to all cells 31 . Non-neuronal functions of b CaMK-II, however, are suggested by the embryonic lethality of a transgenic mouse strain in which b w x CaMK-II is disrupted 32 and the identification of a non-neuronal isozyme of b CaMK-II in rat pancrew x atic cells 33 . Tissue-specific expression of CaMK-II genes and of their splice variants has been reported w x for g CaMKII's 34,35 . d CaMK-II isozymes are expressed in both neuronal and non-neuronal cells, with two domains of variability leading to over 6 w x different splice variants 13,36,37 .
Although CaMK-II has been implicated in mammalian growth control during G1, it is not known which CaMK-II isozymes are expressed in proliferative cells and therefore which ones might be involved in regulating growth. A comprehensive analysis of CaMK-II isozyme expression in non-neuronal, undifferentiated cells has been lacking. In this study, the entire spectrum of CaMK-II isozymes expressed in a panel of human tumor cell lines was characterized by using PCR primers which were conserved amongst all CaMK-II's. The partial cDNA sequence of 6 human b, g and d CaMK-II splice variants is reported, some of which are novel and may be preferentially expressed in tumor cells.
Materials and methods

Cell lines and culture
The following cell lines were used to prepare RNA and are indicated with tumor type of origin and Ž . . Foster City CA . Primary PCR reactions were conducted for 20 cycles with 1 min at 928C, 1.5 min at 428C and 2 min at 728C. Nested secondary PCR reactions were conducted with 2 ml of the primary reaction diluted in 50 ml total volume and cycled 35 times with 1 min at 928C, 1.5 min at 508C and 2 min at 728C. PCR amplification conditions were optimized for MgCl concentration and hybridization 2 temperature using CaMK-II clones and for the minimum cycle number and cDNA concentration necessary to achieve strong bands from brain cDNA, which was known to express all CaMK-II mRNAs. PCR primers were designed from the variable domain of CaMK-II, which is at the C-terminal end of the CaM-binding domain and where almost all of the variability exists among isozymes. The sense primer for the primary PCR reactions was 5
X -GGGACA-CAGTGACACCTGAAGC-3 X , corresponding to Ž amino acids WDTVTPEA residues 238-245 in hu-. man g CaMK-II and the anti-sense primer was To further define isozyme expression in various Ž . cell lines Fig. 4 , nested PCR was again used under the same conditions described above. After the same Fig. 1 . CaMK-II primary structure and PCR primer design. All 4 mammalian CaMK-II genes are composed of catalytic, regulatory, Ž . variable and association regions. PCR primers arrows which were common to all CaMK-II's were used to amplify sequences contained within the variable and a portion of the association region. Fig. 2 . CaMK-II variable region amplification and cloning by RT-PCR from mammary tumor cells. Oligo dT-primed first strand cDNA from ZR-75-1 mammary tumor cells was subjected to PCR using the primers designated in Fig. 1 . The resulting PCR Ž . products lanes 1 and 8: MIX were directly cloned. Clones were then re-amplified with the same primer set and separated on a 3% Ž . agarose gel to reveal 6 size classes I-VI .
( )
PCR primers used in Fig. 2 were used in primary reactions on first strand cDNA, the following antisense primers for a , b, g and d CaMK-II were used in the secondary PCR reaction with the 'GAILT-TML' sense primer. For a CaMK-II: 
Cloning and sequencing
PCR products were cloned directly into the 'TrA' Ž . cloning vector, pCR-II Invitrogen, San Diego CA . Plasmid DNA was then purified from isolated clones w x using selective isopropanol precipitation 39 . Sequencing was conducted in duplicate by SP6 or T7 primed fluorescently tagged dideoxynucleotide termiw x nator sequencing reactions 42 for automated se-Ž . quencing Applied Biosystems, Foster City, CA . Consensus sequences from at least 3 separate clones were used to compile the final sequences reported. GenBank Accession Numbers are U50358 for b , e U50359 for g , U50360 for g , U50361 for d and
Cytosol preparation
In order to examine both CaMK-II activity and immunoreactive polypeptides, cytosolic fractions were prepared from cells harvested by either scraping or detaching with trypsin-EDTA and rinsing centrifu-Ž . Ž gally 2000 = g for 5 min with PBS phosphate . buffered saline containing 5 mM EDTA. Cellular pellets were dissolved in 3 volumes of homogenization buffer, which consisted of 20 mM Hepes, pH 7.4, 2.6 mM EDTA, 20 mM MgCl , 80 mM b-2 glycerol phosphate, 50 mM NaF, 0.1 mM dithiothreitol, 0.01 mgrml each chymostatin, leupeptin, aprotinin, pepstatin and soybean trypsin inhibitor Ž . Sigma, St. Louis MO . Dissolved samples were then Ž . sonicated two 5-s bursts on ice , centrifuged at 10 000 = g for 15 min at 48C and either assayed immediately or stored at y708C. Lysates prepared by sonication solubilized over 90% of the total CaMK-II w x as measured by solution assays 23 .
CaMK-II immunoblots
1-10 mg cytosol was diluted with an equal volw x ume of preheated 2 = sample buffer 43 , followed by boiling for 3 min. Protein concentrations were Ž . determined by BCA assay Pierce, Rockford IL in triplicate. Discontinuous SDS gels were prepared with 7% polyacrylamide. Proteins were transferred to nitrocellulose and nitrocellulose was blocked by a 1 h Ž . incubation with 5% bovine serum albumin BSA , 2% normal goat serum in Tris-buffered saline con-Ž . taining 0.05% Tween-20 TBST . The primary antibody incubation was overnight at room temperature Ž with a rabbit polyclonal anti-CaMK-II antibody UBI, . Lake Placid, NY diluted to 1 mgrml in TBSTr1% BSA. This antibody was prepared against an N-terminal and C-terminal peptide immunogen common to all known CaMK-II isozymes. Blots were rinsed 3 times with TBST and then incubated for 1 h at room temperature with 0.25 mgrml biotinylated goat anti-Ž . mouse IgG KPL, Gaithersburg, MD . Blots were rinsed 3 times with TBST and then incubated for 1 h at room temperature with 2.5 mgrml streptavidin-Ž alkaline phosphatase Molecular Probes, Eugene, . OR . After 3 rinses in TBST, blots were rinsed once in 0.1 M NaCl, 50 mM MgCl , 30 mM Tris, pH 9.2 2 ( )and then developed with 50 mgrml nitro blue tetrazolium and 50 mgrml 5-Br, 4-Cl indolyl phosphate in this buffer.
Results
Human tumor cells express as many as 8 different isozymes of CaMK-II
CaMK-II activity has previously been detected in w x non-neuronal proliferative cells 23,25 and has been w x implicated in the regulation of growth control 22,23 . In order to further investigate the role of CaMK-II in growth control, this study used a comprehensive strategy to identify all expressed CaMK-II isozymes in human tumor and in other non-transformed cell lines. Since isozyme complexity is believed to be accomplished by alternative splicing in each of the Ž . w x four mammalian a, b, g and d CaMK-II genes 9 in a domain which spans the variable domain and a portion of the association domain, PCR primers were chosen which bracketed this entire region and were Ž . common to all CaMK-II's Section 2, Fig. 1 . Nested sets of PCR primers were used to amplify sequences from oligo dT-primed cDNA. PCR amplification con-Ž ditions were optimized using brain cDNA see Sec-. tion 2 . When RNA from the human mammary tumor cell line, ZR-75-1, was used as the template for cDNA synthesis and PCR, a mixture of bands be-Ž . tween 350 and 550 bp Fig. 2 , lanes 1 and 8: Mix was observed. This entire mixture was directly cloned, without fractionation and 85 positive clones were then evaluated. Upon amplification with the same primer set, each clone exhibited one of the bands from the PCR mixture in the size range of 350 to 550 bp. A representative clone from each one of the 6 Ž . Ž . size classes I-VI is shown lanes 2-7 . Approx. 70% of these clones were in class VI, reflecting the predominance of this size band in the initial PCR product mixture. All other classes were approximately equally represented.
Two to five clones representing each cDNA class Ž . were sequenced Fig. 3 . Sequencing confirmed that each of the 6 separate size classes shown in Fig. 2 represented distinct CaMKII cDNA types. Of the 6 cDNA classes, I,II,III and V were most similar to known g CaMK-II isozymes, IV was most like b CaMK-II and VI like d CaMK-II. Classes II and V were identical to human CaMK-II g and g , respec-B C w x tively, at the nucleotide level 34 . Two additional CaMK-II isozymes were cloned in a similar way from cDNA from the LAN5 neuroblastoma cell line. These two additional clones were most like a b CaMK-II and a d CaMK-II, respectively. 
Human tumor cells express a unique pallern of CaMK-II isozymes
Based in part on the human sequences reported here, four additional PCR primer sets were prepared in order to screen cDNA's from a wide variety of different human cell types for the expression of CaMK-II variants from the four mammalian CaMK-II genes. These additional primers were also nested Ž within the first primer set used in Fig. 1 . tively were consistently seen in every nonneuronal cell line examined, in contrast to the absence of a CaMK-II and the variable expression of b CaMK-II. Since these comparative studies were done simultane- 
Discussion
This study has identified at least 8 separate CaMK-II isozymes which are expressed in human cell lines derived from a wide variety of tumors, but which are absent from adult neuronal tissue. The 8 tumor cell CaMK-II isozymes described here are products of the Ž Although the role of each of these isozymes in cell function is not yet known, the expression of over 20 CaMK-II isozymes is consistent with the multiple functions implicated for CaMK-II, including memory, secretion, metabolism and cell growth control. The results presented here confirm that CaMK-II expression is modulated at the level of mRNA splicing. Tumor cell lines, including the neuroblastoma cell line, LAN5 and the H146 small cell lung carcinoma cell line, which is of neuroendocrine origin, lose almost every neuronal-specific CaMKII isozyme, even though 3 of the 4 CaMK-II genes continue to express product.
Careful examination of the sequence of all known CaMK-II isozymes has revealed ten separate domains Ž . which are subject to splicing Fig. 6 . Each of these domains may have a particular function which may be associated with the cell type in which the Ž . isozyme s which contain that domain are expressed.
Ž . The boundaries of these domains I-X were derived from the known intron-exon structure of b CaMK-II w x 32 and from cDNA's whose exon boundaries are not known, but were predicted from differences between isozymes. As shown, each of these domains has similar length and sequence between genes, although some domains are gene-specific. Each known CaMK-II variant is composed of between 3 and 7 of these separate domains, presumably achieved through alternative splicing. The lines connecting these do-Ž . mains Fig. 6 represent all known possibilities.
Variations in the domain use among the four CaMK-II genes occur in a progressively complex manner suggestive of an evolutionary hierarchy. For example, in bctween the two 'tether' domains, II and VII, the only optional domain in a CaMK-II is domain III and in b CaMK-II, domain VI. In contrast, g and d CaMK-II optional domains include all of those between III and VI. In other words, g and d CaMK-II use a combination of domain options from a and b CaMK-II. Further options, particular to b, g and d CaMK-II on both the N-terminal side of domain II and the C-terminal side of domain VII, increase the number of existing and potential gene products. These observations suggest that a shift in splicing signals could act similarly upon all CaMK-II genes to restrict or expand the spectrum of isozymes expressed in different tissues.
All CaMK-II's can be described based on the presence or absence of domains. All 8 of the tumor cell CaMK-II isozymes identified here and implicated Ž . from isozyme-specific PCR Fig. 4 , lack domain I. In fact, domain I has only been found in neuronalspecific b and g isozymes; it is missing from every non-neuronal CaMK-II isozyme identified. It has been suggested that domain I may influence the binding w x affinity for CaM 13 since it resides on the catalytic Ž . side of the invariant tether domain II . In b CaMK-II, the exon just prior to domain I comprises the C- Domain II represents the invariable 'tether' domain found in every CaMK-II isozyme. It is thought to connect the regulatory and variable regions. Domain III is found in only 3 cDNA's and is responsiw x ble for nuclear targeting 14 . Of the tumor cells evaluated here, none expressed a putative nuclear targeted CaMK-II isozyme. CaMK-II has been rew x ported in the nucleus of proliferative cells 48 and may contribute to the regulation of gene expression w x 11 , however, none of the 8 CaMK-II isozymes found in human tumor cells contain this nuclear localization sequence and would therefore not be expected to be targeted to the nucleus. CaMK-II need not enter the nucleus to function in regulating cell growth control; it could act through the modification of a cytoplasmic member of the growth signaling cascade, as suggested by its kinetics of activation w x 26 .
Domain IV, rich in basic amino acids is found in g , g , g , b X and b . Neither this domain nor Domain VI is found in all g isozymes including g , g , g and g Within domain VI, Thr 382 is B C G H w x rapidly autophosphorylated in b CaMK-II 9,30 , but the result of its phosphorylation is not known. Of domains IV, V and VI, each tumor cell CaMK-II contains between 1 and 3 of these domains, except for d , which contains none. C Domain VII is found in every CaMK-II; its length and three quarters of its amino acids are absolutely invariant. This domain has a net charge of y4 to y5 and contains between 29 and 41% serine or threonine residues. It is believed to be at the beginning of the 'association domain' and is therefore analogous to domain II, serving as a conserved tether between the variable and association domains.
Domains VIII and IX are specific to the g CaMK-II gene. Domain VIII is a 10 amino acid domain specific to g , g and g while domain IX is a 28 D E F amino acid insert specific to g , g , g and g . defines another potential exon boundary not previously realized. Domain X is a b CaMK-II-specific proline-rich domain described only in CaMK-II b from the rat 3 w x pancreas 33 . This domain was not identified, howw x ever, in the genomic mouse CaMK-II sequence 32 . Interestingly, this domain conforms to SH3-binding sequences, and may therefore be targeted directly to w x the growth factor machinery 33 . These domains could also target isozymes to subcellular sites or substrates or influence the oligomeric nature of CaMK-II.
There are several additional mammalian d CaMK-II isozymes whose variability is additionally conferred at the distal C-terminus, where the last 21 w x amino acids are either inserted or deleted 36 . These additions are specific to d CaMK-II's. Fig. 6 reveals that CaMK-II d , like CaMK-II a, contains only 2 C of the 7 possible variable domains in the variable region.
In summary, the results presented here suggest that at some point in neuronal tumorigenesis, the a CaMK-II gene is turned off and the splicing signals amongst the other three CaMK-II genes are similarly changed; i.e., all new variants are truncated with similar domain omissions. These results also suggest that the opposite change in CaMK-II splicing accompanies differentiation since undifferentiated embryonic fibroblasts have a pattern distinct from adult differentiated neuronal tissue and much more like that of tumor cells.
Transformed cells have previously been shown to undergo alterations in their dependence on Ca 2q , in their level of CaM and in CaM binding proteins w x 3,49-54 . This report now shows that they also undergo changes in the expression pattern of CaMK-Ž . II. Although it is not known which isozyme s may regulate cell growth in human tumor cells, the inappropriate expression of CaMKII variants in tumor cells may contribute to the malignant phenotype.
